Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784260 | 0.93 | CHRM1 (1.00) | CHRM1CHRM2CHRM3 | |
| SCHEMBL4511492 | 0.86 | CHRM1 (1.00) | CHRM1CHRM2CHRM3 | |
| SCHEMBL6785589 | 0.85 | CHRM1 (0.71) | CHRM1CHRM2CHRM3 | |
| SCHEMBL6781848 | 0.83 | CHRM1 (0.73) | CHRM1 | |
| SCHEMBL6783800 | 0.83 | CHRM1 (0.73) | CHRM1CHRM2CHRM3 | |
| SCHEMBL6911494 | 0.78 | CHRM1 (0.69) | CHRM1 | |
| SCHEMBL7819046 | 0.78 | CHRM1 (0.59) | CHRM1 | |
| SCHEMBL8502069 | 0.78 | CHRM1 (0.67) | CHRM1 | |
| SCHEMBL18004204 | 0.77 | CHRM1 (1.00) | CHRM1CHRM2CHRM3 | |
| Hydrochloric Acid SCHEMBL29400173 | 0.76 | CHRM1 (1.00) | CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | claimed |
| WO-1998027983-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1998-07-02 | — | — | WO | claimed |
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998027983-A1 | A METHOD OF TREATING HYPERCHOLESTEROLEMIA AND RELATED DISORDERS | NOVO NORDISK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | CHRM1 5/4885CHRM2 3/4885CHRM3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.